Cargando…

Management of vitiligo with topical janus tyrosine kinase inhibitor therapy: An evidence-based review

Detalles Bibliográficos
Autores principales:	Abduelmula, Abrahim, Mufti, Asfandyar, Chong, Derrick HY., Sood, Siddhartha, Sachdeva, Muskaan, Yeung, Jensen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634355/ https://www.ncbi.nlm.nih.gov/pubmed/36339066 http://dx.doi.org/10.1016/j.jdin.2022.09.003

Ejemplares similares

The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based Review
por: Abduelmula, Abrahim, et al.
Publicado: (2023)

Management of Alopecia Areata With Topical JAK Inhibitor Therapy: An Evidence-Based Review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

Biologic treatment outcomes in refractory bullous pemphigoid: An evidence-based review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

Drugs Associated With the Development of Palmoplantar Keratoderma: A Systematic Review
por: Mirali, Sara, et al.
Publicado: (2021)

Treatment outcomes in patients with papuloerythroderma of Ofuji: A systematic review
por: Mufti, Asfandyar, et al.
Publicado: (2021)

A Systematic Review Characterizing Psoriatic Arthritis Onset and Exacerbation in Patients Receiving Biologic Therapy
por: Sachdeva, Muskaan, et al.
Publicado: (2022)

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Clinical manifestations and treatment outcomes in prurigo pigmentosa (Nagashima disease): A systematic review of the literature
por: Mufti, Asfandyar, et al.
Publicado: (2021)

A systematic review of vitiligo onset and exacerbation in patients receiving biologic therapy
por: Sachdeva, Muskaan, et al.
Publicado: (2020)

Reply to: “Skin damage among health care workers managing coronavirus disease 2019”
por: Maliyar, Khalad, et al.
Publicado: (2020)

Dermatology: how to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Association of myalgias with compounded topical Janus kinase inhibitor use in vitiligo
por: Narla, Shanthi, et al.
Publicado: (2020)

Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment
por: Sachdeva, Muskaan, et al.
Publicado: (2020)

Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient
por: Berbert Ferreira, Sineida, et al.
Publicado: (2021)

Eruptive Seborrheic Keratoses Are Associated With a Co-Occurring Malignancy in the Majority of Reported Cases: A Systematic Review
por: Mirali, Sara, et al.
Publicado: (2021)

Biologic therapy for refractory pemphigoid gestationis: An evidence-based systematic review
por: Sood, Siddhartha, et al.
Publicado: (2023)

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
por: Qi, Fei, et al.
Publicado: (2021)

Modifications to dermatology residency education during the COVID-19 pandemic
por: Mufti, Asfandyar, et al.
Publicado: (2020)

Hereditary haemorrhagic telangiectasia: A case report
por: Mufti, Asfandyar, et al.
Publicado: (2021)

COVID-19 and wound care: A Canadian perspective
por: Mufti, Asfandyar, et al.
Publicado: (2020)

Squamous cell carcinoma arising within discoid lupus erythematous lesions: A systematic review
por: Mufti, Asfandyar, et al.
Publicado: (2020)

Immunohistochemistry of Janus Kinase 1 (JAK1) Expression in Vitiligo
por: Abdou, Asmaa Gaber, et al.
Publicado: (2018)

Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review
por: Sachdeva, Muskaan, et al.
Publicado: (2021)

Treatment outcomes of biologics and small molecules for chronic hand eczema: An evidence-based systematic review
por: Sood, Siddhartha, et al.
Publicado: (2023)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
por: Lytvyn, Yuliya, et al.
Publicado: (2021)

Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition
por: Nikolopoulos, Dionysis, et al.
Publicado: (2023)

Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo
por: Samaka, Rehab M, et al.
Publicado: (2019)

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
por: Chimalakonda, Anjaneya, et al.
Publicado: (2021)

Micro - Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo
por: Gianfaldoni, Serena, et al.
Publicado: (2018)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

Topical Janus kinase inhibitors in atopic dermatitis: a safety network meta-analysis
por: Alves, Carlos, et al.
Publicado: (2023)

Janus kinase inhibitors: jackpot or potluck?
por: Pavithran, Keechilat, et al.
Publicado: (2012)

Janus Kinase Inhibitors and Cell Therapy
por: Assal, Amer, et al.
Publicado: (2021)

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
por: BALLANGER, Fabienne, et al.
Publicado: (2023)

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
por: Veale, Douglas J, et al.
Publicado: (2019)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Janus kinase inhibitors for the therapy of atopic dermatitis
por: Traidl, Stephan, et al.
Publicado: (2021)

Role of Janus Kinase Inhibitors in Therapy of Psoriasis
por: Słuczanowska-Głąbowska, Sylwia, et al.
Publicado: (2021)

Janus kinase inhibitors in autoimmune bullous diseases
por: Huang, Dawei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6006b227ptfb1lcm8s898j6d1q